Capsule FMT促进癌症免疫疗法,提高反应率和减少试验的副作用。 Capsule FMT boosts cancer immunotherapy, improving response rates and reducing side effects in trials.

根据在《自然医学》上发表的多项研究,以胶囊形式提供的胎儿微生物移植(FMT)在提高癌症免疫疗法效果和减少严重副作用方面显示了希望。 Fecal microbiota transplants (FMT) delivered in capsule form show promise in boosting cancer immunotherapy effectiveness and reducing severe side effects, according to multiple studies published in Nature Medicine. 在涉及肾癌、肺癌和黑瘤癌症的试验中,健康捐助者的FMT反应率提高——肺癌达到80%,黑瘤达到75%——而典型的响应率为39-58%。 In trials involving kidney, lung, and melanoma cancers, FMT from healthy donors improved response rates—reaching 80% in lung cancer and 75% in melanoma—compared to typical rates of 39–58%. 对于先进的肾癌,从免疫疗法反应者处接受FMT治疗的病人,在安慰剂组中,中位无进展存活率为24个月,而9个月为无进展存活率,疾病发病风险降低50%。 For advanced kidney cancer, patients receiving FMT from immunotherapy responders had a median progression-free survival of 24 months versus nine months in the placebo group, with a 50% reduced risk of disease progression. FMT还帮助减少了治疗限制的副作用,如脊髓炎和腹泻。 FMT also helped reduce treatment-limiting side effects like colitis and diarrhea. 这些在安大略伦敦开发的胶囊现已成为更大规模的泛加拿大试验的一部分,突出了可扩展、个性化微生物疗法的潜力。 The capsules, developed in London, Ontario, are now part of a larger pan-Canadian trial, highlighting potential for scalable, personalized microbiome therapies.